Physician

Michael Brian Chang, M.D.

According to 2025 Medicare claims, Michael Chang, M.D. (NPI: 1326337122) practices dermatology in the Albuquerque, NM market, with the plurality of this provider's patient population coming from Bernalillo, NM. This provider's primary affiliated billing organization is DERMATOLOGY & SKIN CANCER CENTER OF NM PC (NPI: 1235264284; TIN: 208234423) and primary practice location at 87109-4366.

Chang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 909 traditional Medicare patients, billed 6,031 HCPCS/CPT codes, and received $501,782 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 758 prescription claims across 363 beneficiaries totaling $118,084 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 5 records totaling $220. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $27,350 to $501,782. Similarly, Part D prescription costs have moved sharply higher in recent years, from $24,794 to $118,084. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$251K$502K2015 Medicare payment: $27,350 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $163,487 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $346,110 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $426,508 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $436,831 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $405,681 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $443,693 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $447,592 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $484,190 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $501,782 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015291782$27,350
20163151,498$163,487
20175563,308$346,110
20187274,476$426,508
20197214,735$436,831
20206885,172$405,681
20218266,085$443,693
20229307,013$447,592
20239256,285$484,190
20249096,031$501,782

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$71K$142K2015 Drug cost: $24,794 (USD; Tot_Drug_Cst)2016 Drug cost: $7,093 (USD; Tot_Drug_Cst)2017 Drug cost: $22,591 (USD; Tot_Drug_Cst)2018 Drug cost: $28,281 (USD; Tot_Drug_Cst)2019 Drug cost: $27,332 (USD; Tot_Drug_Cst)2020 Drug cost: $27,142 (USD; Tot_Drug_Cst)2021 Drug cost: $102,106 (USD; Tot_Drug_Cst)2022 Drug cost: $142,464 (USD; Tot_Drug_Cst)2023 Drug cost: $110,959 (USD; Tot_Drug_Cst)2024 Drug cost: $118,084 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015190352$24,794
2016133189$7,093
2017203401$22,591
2018208380$28,281
2019224445$27,332
2020229465$27,142
2021289558$102,106
2022323603$142,464
2023355666$110,959
2024363758$118,084

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17311Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks299364$472
11102Biopsy of related skin growth, first growth208250$62
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more568757$57
17000Destruction of precancer skin growth, 1 growth477657$36
17003Destruction of precancer skin growth, 2-14 growths3802,368$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Humira(Cf) PenAdalimumab14392$90,714
FluocinonideFluocinonide771,997$3,810
FluorouracilFluorouracil26993$2,704
CephalexinCephalexin1171,325$1,909
KetoconazoleKetoconazole1324,153$1,737

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.5$220Janssen Scientific Affairs, LLC
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Brian Chang, M.D.?

Tedicare shows public-source Medicare data for Michael Brian Chang, M.D. (NPI 1326337122), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Brian Chang, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Brian Chang, M.D.?

Michael Brian Chang, M.D. is linked to DERMATOLOGY & SKIN CANCER CENTER OF NM PC (billing NPI 1235264284) in the available physician profile data.

Does Michael Brian Chang, M.D. have Open Payments data?

Michael Brian Chang, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.